Envoy Medical, Inc.
COCH- Exchange
- Nasdaq
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001840877
No open-market purchases or sales by Envoy Medical, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $19.9M in total; no superinvestor holds it.
Other share classesCOCHW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 31
- 13F valueReported value at the end of Q2 2026
- $19.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding COCH, Q2 2026
No superinvestor reported holding COCH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Envoy Medical, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 (view filing)4:51 PM ET | Feb 12 | 5 days | Patel Mona ChetanDirector | PPurchaseClass A Common Stock | +312.5K | $0.40 | +$125.0K | +1,562.5%332.5K after | |
| Feb 17, 2026 (view filing)4:51 PM ET | Feb 12 | 5 days | Patel Mona ChetanDirector | PPurchaseClass A Common Stock | +500.0K | $0.00 | $0 | –312.5K after | Derivative2 lots |
| Feb 17, 2026 (view filing)4:49 PM ET | Feb 12 | 5 days | Potashnick RobertInterim CFO | PPurchaseClass A Common Stock | +212.5K | $0.40 | +$85.0K | New position212.5K after | |
| Feb 17, 2026 (view filing)4:49 PM ET | Feb 12 | 5 days | Potashnick RobertInterim CFO | PPurchaseClass A Common Stock | +340.0K | $0.00 | $0 | –212.5K after | Derivative2 lots |
| Feb 17, 2026 (view filing)4:47 PM ET | Feb 12 | 5 days | Kantor SusanDirector | PPurchaseClass A Common Stock | +96.2K | $0.40 | +$38.5K | +123.4%174.0K after | |
| Feb 17, 2026 (view filing)4:47 PM ET | Feb 12 | 5 days | Kantor SusanDirector | PPurchaseClass A Common Stock | +153.8K | $0.00 | $0 | –96.2K after | Derivative2 lots |
| Feb 17, 2026 (view filing)4:45 PM ET | Feb 12 | 5 days | Brynelsen CharlesDirector | PPurchaseClass A Common Stock | +1.00M | $0.40 | +$400.0K | +2,000.0%1.05M after | |
| Feb 17, 2026 (view filing)4:45 PM ET | Feb 12 | 5 days | Brynelsen CharlesDirector | PPurchaseClass A Common Stock | +1.60M | $0.00 | $0 | –1.00M after | Derivative2 lots |
| Feb 17, 2026 (view filing)4:45 PM ET | Feb 12 | 5 days | Lucas Brent T.Chief Executive Officer | PPurchaseClass A Common Stock | +62.5K | $0.40 | +$25.0K | +26.6%297.1K after | |
| Feb 17, 2026 (view filing)4:45 PM ET | Feb 12 | 5 days | Lucas Brent T.Chief Executive Officer | PPurchaseClass A Common Stock | +100.0K | $0.00 | $0 | –62.5K after | Derivative2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Envoy Medical, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 15,300,000 | $11.9M | 0.36% | +7,650,000+100.0% | Added |
| Bleichroeder LP | 6,250,000 | $4.95M | 0.89% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 880,214 | $697.1K | 0.00% | −1,458−0.2% | Reduced |
| DSG Capital Advisors, LLC | 625,000 | $474.2K | 0.07% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 541,729 | $429.1K | 0.00% | +19,905+3.8% | Added |
| Colony Group, LLC | 425,310 | $336.8K | 0.00% | +212,655+100.0% | Added |
| Vanguard Fiduciary Trust Co | 296,679 | $235.0K | 0.00% | +1,958+0.7% | Added |
| UBS Group AG | 190,838 | $151.1K | 0.00% | +120,379+170.8% | Added |
| Arcus Capital Partners, LLC | 187,573 | $148.6K | 0.06% | 00.0% | Unchanged |
| ExodusPoint Capital Management, LP | 182,354 | $144.4K | 0.00% | +182,354 | New |